Citi analyst Samantha Semenkow anticipates FDA experts' posi...
Citi analyst Samantha Semenkow anticipates FDA experts' positive stance on exa-cel, similar to Zynteglo and Skysona last year. She suggests Beam shares could increase 10%-30% following favorable FDA commentary and sees buoyant future for Editas Medicine on expected AdCom and EDIT-301 data readout.
Editas Upgraded at Citi Ahead of FDA AdCom on Gene Editing Therapy
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more
Comment
Sign in to post a comment